Report accuses Covid vaccine makers of putting profits before lives
Only 0.3% of the 5.76 billion doses administered worldwide have been distributed to low-income countries
In a new report commissioned by Amnesty International, six pharma companies heading the global roll-out of Covid-19 vaccines have been criticised for refusing to waive intellectual property rights and share vaccine technology.
Amnesty International has said that such refusal, along with failing to prioritise vaccine deliveries to poorer countries, is "fuelling an unprecedented human rights crisis".
The report A Double Dose of Inequality: Pharma companies and the Covid-19 vaccines crisis, assessed AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer and concluded that the industry is "woefully failing to respect human rights".
In a statement, Agnès Callamard, Amnesty International’s Secretary General, said that Big Pharma's intentional blocking of knowledge transfer, along with their "wheeling and dealing in favour of wealthy states" has created a "predictable" and "devastating" vaccine scarcity for others.
By the end of 2022, BioNTech, Moderna and Pfizer combined are set to make a $130 billion – a fact which serves to underscore their putting profits before lives, said Agnès Callamard.
The report also revealed that out of 5.76 billion doses administered worldwide, only 0.3% have been distributed to low-income countries. Furthermore, some of the assessed companies have continued to stock up vaccine supplies for states known to be hoarding the vaccine.
So far, all companies assessed have refused to take part in internationally coordinated initiatives designed to boost global supply by sharing knowledge and technology. They have also opposed proposals to temporarily lift intellectual property rights,
To coincide with the publication of the report, Amnesty International is launching a global campaign which calls for 2 billion vaccines to be delivered to low and lower-middle income countries before end of the year.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance